Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (412)	7/2/2004 2:09:44 PM
From: rkrw	Read Replies (1) \| Respond to of 508

Interesting bombshell in there.... Press Release Source: The Law Firm of Goodkind Labaton Rudoff & Sucharow LLP Goodkind Labaton Rudoff & Sucharow LLP Announces Recent Updates in Class Action Lawsuit Against InterMune Inc. Tuesday June 29, 1:14 pm ET NEW YORK--(BUSINESS WIRE)--June 29, 2004--Goodkind Labaton Rudoff & Sucharow LLP announces recent updates in the class action litigation filed in the United States District Court for the Northern District of California, on behalf of persons who purchased or otherwise acquired publicly traded securities of InterMune Inc. ("InterMune" or the "Company") (NASDAQ:ITMN - News) between January 7, 2003 and June 11, 2003, inclusive. By order dated November 26, 2003, (the "Order") Goodkind Labaton was appointed by the Court to serve as lead counsel for the Class in the now consolidated action In re InterMune Inc. Securities Litigation, Civil Action No. 03-2954 SI (N.D. Cal). On January 30, 2004 Goodkind Labaton filed a consolidated amended complaint, which is available on the firm's web site at www.glrslaw.com. Goodkind Labaton continues to conduct an extensive investigation that to date has revealed significant findings.******Goodkind Labaton's investigation has been aided, in large part, by the assistance of certain former employees of InterMune.**** If you are a former employee or have pertinent information relevant to the investigation, please feel free to contact Ira Schochet at (800) 321-0476.